Allied Healthcare Group reports successful trial results for HPV vaccine

Allied Healthcare Group, an Australian biomedical company, announced the successful results on Thursday of the initial study of its novel human papillomavirus vaccine.

The vaccine is being developed by Allied's investment company Coridon, which is led by Ian Frazer. The vaccine is meant to combat existing HPV infection and prevent and treat the onset of cancer.

Frazer developed the existing vaccines Gardasil and Cervarix, which are only effective in preventing transmission of the virus, a common precursor to cervical cancer.

Results from a preclinical study confirmed that the Coridon vaccine induced an immune response to protect mice from developing cancer tumors connected with infection from HPV.

"These are very promising results for this program," Lee Rodne, the group managing director of Allied Healthcare Group, said. "We are moving another step closer to developing a therapeutic treatment for HPV-associated cervical cancer. Given the wide benefits associated with Professor Frazer's blockbuster vaccines Gardasil and Cervarix, we are very excited by the possibility of developing a vaccine, that can not only prevent infection, but can also stop the development of disease in people that have already been infected."

The targeted DNA vaccine clears HPV transformed cells, representing a new strategy to protect against cancers caused by existing HPV infections.

"This finding further confirms through preclinical studies the potential of Coridon's technologies for developing successful immunotherapies" Frazer said.

HPV is one of the most common sexually transmitted diseases in the world and is associated with cervical cancer, head cancer, neck cancer and anogenital cancers. Cervical cancer causes approximately 288,000 deaths annually, according to the World Health Organization.